- Home
- PBFS vs BMEA Comparison
PBFS vs BMEA Comparison
Compare PBFS & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- BMEA
- Stock Information
- Founded
- PBFS 1889
- BMEA 2017
- Country
- PBFS United States
- BMEA United States
- Employees
- PBFS N/A
- BMEA N/A
- Industry
- PBFS Banks
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- PBFS Finance
- BMEA Health Care
- Exchange
- PBFS Nasdaq
- BMEA Nasdaq
- Market Cap
- PBFS 277.5M
- BMEA 275.6M
- IPO Year
- PBFS N/A
- BMEA 2021
- Fundamental
- Price
- PBFS $11.45
- BMEA $6.53
- Analyst Decision
- PBFS
- BMEA Buy
- Analyst Count
- PBFS 0
- BMEA 13
- Target Price
- PBFS N/A
- BMEA $37.25
- AVG Volume (30 Days)
- PBFS 28.9K
- BMEA 817.8K
- Earning Date
- PBFS 11-12-2024
- BMEA 10-29-2024
- Dividend Yield
- PBFS N/A
- BMEA N/A
- EPS Growth
- PBFS N/A
- BMEA N/A
- EPS
- PBFS 0.72
- BMEA N/A
- Revenue
- PBFS $78,364,000.00
- BMEA N/A
- Revenue This Year
- PBFS N/A
- BMEA N/A
- Revenue Next Year
- PBFS N/A
- BMEA N/A
- P/E Ratio
- PBFS $16.02
- BMEA N/A
- Revenue Growth
- PBFS N/A
- BMEA N/A
- 52 Week Low
- PBFS $7.97
- BMEA $3.61
- 52 Week High
- PBFS $11.86
- BMEA $22.74
- Technical
- Relative Strength Index (RSI)
- PBFS 57.80
- BMEA 23.64
- Support Level
- PBFS $11.36
- BMEA $8.60
- Resistance Level
- PBFS $11.85
- BMEA $9.34
- Average True Range (ATR)
- PBFS 0.30
- BMEA 0.79
- MACD
- PBFS 0.01
- BMEA -0.40
- Stochastic Oscillator
- PBFS 46.34
- BMEA 0.82
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting, and Insurance.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.